Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation " [1 K8 C2 z& ^! f9 YGenomic characterization of recurrent breast and lung tumors developed over the course of 10 years in a 29-year-old patient with a germline p53 mutation (Li-Fraumeni Syndrome) identified oncogenic alterations in the HER2 and EGFR genes across all tumors, including HER2 amplifications, an EGFR-exon 20 insertion, and the first-in-human HER2-V659E mutation showing a phenotypic convergent evolution towards HER2 and EGFR alterations. Following the identification of HER2-activating events in the most recent lung carcinoma and in circulating tumor cells, we treated the reminiscent metastatic lesions with a lapatinib-based therapy. A clinical response both symptomatic and radiologic was achieved. HER2-V659E sensitivity to lapatinib was confirmed in the laboratory.
老马你好:现需要你的帮助。8 J# a- X, R# W f1 Q' A& Q3 k6 W( w
我每次打算换药的时候都很茫然无助,虽然在线时间那么长了,始终没掌握好该如何换药。( w2 G! K: M- X
我家用过两次阿瓦+键泽了,效果很好,我父亲的情况下一步用什么药好?) I5 l' M5 C) @$ R# Y. s6 y9 z
我家的治疗贴http://www.yuaigongwu.com/thread-11018-1-1.html